Sofosbuvir plus daclatasvir in treatment of chronic hepatitis C genotype 4 infection in a cohort of Egyptian patients: An experiment the size of egyptian village

International Journal of Hepatology

Volumn 2018, Issue , 2018, Pages

  Ahmed, Ossama Ashraf ^a   Safwat, Eslam ^a   Khalifa, Mohamed Omar ^a   Elshafie, Ahmed I ^a   Fouad, Mohamed Hassan Ahmed ^a   Salama, Mohamed Magdy ^a   Naguib, Gina Gamal ^a   Eltabbakh, Mohamed Mahmoud ^a   Sherief, Ahmed Fouad ^a   Abd Elsalam, Sherief ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b TANTA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; DACLATASVIR; HEPATITIS B SURFACE ANTIGEN; SOFOSBUVIR; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EGYPT; EGYPTIAN; ESTIMATED GLOMERULAR FILTRATION RATE; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS B; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NAUSEA; OBSERVATIONAL STUDY; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; SCREENING; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 85052212182     PISSN: 20903448     EISSN: 20903456     Source Type: Journal    
DOI: 10.1155/2018/9616234     Document Type: Article

References (15)

1. E. Gower, C. C. Estes, S. Hindman, K. Razavi-Shearer, and H. Razavi, "Global epidemiology and genotype distribution of the hepatitis C virus, " Journal of Hepatology, vol. 61, supplement 1, pp. S45-S57, 2014.
2. A. E. M. AlyAbd Elrazek, S. E. Bilasy, A. E. M. Elbanna, and A. E. A. Elsherif, "Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis, "Medicine (United States), vol. 93, no. 28, p. e204, 2014.
3. N. Elwan, A. Elfert, S. Abd-Elsalam et al., "Study of hepatic steatosis index in patients with chronic HCV infection, " International Journal of Current Microbiology and Applied Sciences, vol. 5, no. 5, pp. 266-279, 2016.
4. S. Abd-Elsalam, M. Sharaf-Eldin, S. Soliman, A. Elfert, R. Badawi, and Y. K. Ahmad, "Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice, " Archives of Virology, pp. 1-6, 2017.
5. O. A. Ahmed, H. H. Kaisar, N. Hawash et al., "Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in treatment of a cohort of egyptian patients with hepatitis C virus infection, " Infectious Disorders - Drug Targets, vol. 17, no. 2, pp. 95-100, 2017.
6. G. Bertino, A. Ardiri, M. Proiti et al., "Chronic hepatitis C: this and the new era of treatment, " World Journal of Hepatology, vol. 8, no. 2, pp. 92-106, 2016.
7. D. Banerjee and K. R. Reddy, "Review article: Safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy, " Alimentary Pharmacology & Therapeutics, vol. 43, no. 6, pp. 674-696, 2016.
8. S. Pol, A. Vallet-Pichard, and M. Corouge, "Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life, " Hepatic Medicine: Evidence and Research, vol. 8, pp. 21-26, 2016.
9. E. Hathorn and A. M. Elsharkawy, "Management of hepatitis C genotype 4 in the directly acting antivirals era, " BMJ Open Gastroenterology, vol. 3, no. 1, Article ID e000112, 2016.
10. M. S. Sulkowski, D. F. Gardiner, M. Rodriguez-Torres et al., "Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection, "The New England Journal of Medicine, vol. 370, no. 15, pp. 1469-1469, 2014.
11. H. Fontaine, C. Hezode, F. Zoulim et al., "Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-monoinfected patients from the french observational cohort ANRS CO22 Hepather, " in Proceedings of the 50th Annual Meeting of European Association for the Study of the1 Liver, Vienna, Austria, April 2015.
12. H. Omar, W. El Akel, T. Elbaz et al., "Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt, " Alimentary Pharmacology&Therapeutics, vol. 47, no. 3, pp. 421-431, 2018.
13. M. A. Babatin, A. S. Alghamdi, A. Albenmousa et al., "Efficacy and safety of simeprevir or daclatasvir in combination with sofosbuvir for the treatment of hepatitisCgenotype 4 infection, " Journal of Clinical Gastroenterology, Article ID28767462, 2017.
14. R.Mehta, M. Kabrawala, S.Nandwani et al., "Safety and efficacy of sofosbuvir and daclatasvir for hepatitis C virus infection in patients with β-thalassemia major, " Journal of Clinical and Experimental Hepatology, 2017.
15. A. Elsharkawy, M. El-Raziky, W. El-Akel et al., "Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: lessons from the egyptian experience, " Journal of Hepatology, 2017.